Michael MacManus

6.6k total citations · 1 hit paper
148 papers, 4.5k citations indexed

About

Michael MacManus is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Michael MacManus has authored 148 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Pulmonary and Respiratory Medicine, 72 papers in Radiology, Nuclear Medicine and Imaging and 48 papers in Oncology. Recurrent topics in Michael MacManus's work include Lung Cancer Diagnosis and Treatment (62 papers), Medical Imaging Techniques and Applications (46 papers) and Lymphoma Diagnosis and Treatment (36 papers). Michael MacManus is often cited by papers focused on Lung Cancer Diagnosis and Treatment (62 papers), Medical Imaging Techniques and Applications (46 papers) and Lymphoma Diagnosis and Treatment (36 papers). Michael MacManus collaborates with scholars based in Australia, United States and United Kingdom. Michael MacManus's co-authors include David Ball, Rodney J. Hicks, Shankar Siva, Olga A. Martin, Andrew Wirth, Roger F. Martin, Victor Kalff, Allan F McKenzie, Robert E. Ware and Jason Callahan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Michael MacManus

140 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abscopal effects of radiation therapy: A clinical review for the radiobiologist

2013 346 citations Shankar Siva, Michael MacManus et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael MacManus Australia	36	2.3k	2.3k	1.2k	920	668	148	4.5k
Andrew Quon United States	39	2.0k 0.9×	2.6k 1.2×	1.4k 1.2×	428 0.5×	580 0.9×	114	4.8k
Ivan R. Vogelius Denmark	33	2.3k 1.0×	1.9k 0.8×	928 0.8×	1.9k 2.1×	514 0.8×	162	4.5k
A. Sun Canada	37	2.5k 1.1×	1.1k 0.5×	1.7k 1.4×	891 1.0×	935 1.4×	162	4.9k
Jean‐Marc Cosset France	34	2.3k 1.0×	1.3k 0.6×	762 0.6×	1.2k 1.3×	735 1.1×	126	4.2k
Hans C. Steinert Switzerland	39	2.4k 1.1×	2.9k 1.3×	1.5k 1.2×	469 0.5×	449 0.7×	99	6.0k
Heather A. Jacene United States	30	1.8k 0.8×	3.3k 1.4×	1.7k 1.4×	314 0.3×	737 1.1×	152	5.6k
Jörg Kotzerke Germany	36	1.9k 0.8×	3.0k 1.3×	870 0.7×	380 0.4×	304 0.5×	181	4.8k
Francesco Scopinaro Italy	35	892 0.4×	2.1k 0.9×	874 0.7×	721 0.8×	374 0.6×	217	3.9k
Jeffrey Y.C. Wong United States	43	1.8k 0.8×	2.7k 1.2×	1.5k 1.2×	1.3k 1.4×	250 0.4×	214	5.4k
Nicolaus Andratschke Switzerland	39	3.1k 1.4×	2.2k 1.0×	1.3k 1.0×	2.1k 2.2×	286 0.4×	246	5.6k

Countries citing papers authored by Michael MacManus

Since Specialization

Citations

This map shows the geographic impact of Michael MacManus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael MacManus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael MacManus more than expected).

Fields of papers citing papers by Michael MacManus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael MacManus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael MacManus. The network helps show where Michael MacManus may publish in the future.

Co-authorship network of co-authors of Michael MacManus

This figure shows the co-authorship network connecting the top 25 collaborators of Michael MacManus. A scholar is included among the top collaborators of Michael MacManus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael MacManus. Michael MacManus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Erku, Daniel, Joshua W.D. Tobin, John F. Seymour, et al.. (2025). An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early‐Stage Follicular Lymphoma. eJHaem. 6(1). e70002–e70002.

Hawkes, Eliza A., Jodie Palmer, Richard Khor, et al.. (2025). T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial. Blood Advances. 9(20). 5263–5273.

Tobin, Joshua W.D., Greg Hapgood, Anna Johnston, et al.. (2024). Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 54(8). 1384–1395. 2 indexed citations

Campbell, Belinda A., Alessandro Lambertini, Michael S. Hofman, et al.. (2023). Are dynamic or fixed FDG‐PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B‐cell lymphoma undergoing autologous haematopoietic stem cell transplantation?. British Journal of Haematology. 201(3). 502–509. 2 indexed citations

Lobb, Richard J., Emma L. Norris, Marcus L. Hastie, et al.. (2023). An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer. Communications Biology. 6(1). 68–68. 19 indexed citations

MacManus, Michael, Laura Kirby, Benjamin J. Blyth, et al.. (2023). Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC. Clinical and Translational Radiation Oncology. 43. 100682–100682. 4 indexed citations

MacManus, Michael, et al.. (2023). Assessment of lung doses in patients undergoing total body irradiation for haematological malignancies with and without lung shielding. Journal of Medical Imaging and Radiation Oncology. 67(6). 684–690.

Kron, Tomas, Alan Herschtal, Nicholas Hardcastle, et al.. (2023). Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 117(2). 378–386. 4 indexed citations

Hegi‐Johnson, Fiona, Stacey E. Rudd, Christian Wichmann, et al.. (2022). ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with ⁸⁹ Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ Open. 12(11). e056708–e056708. 15 indexed citations

10.

Alipour, Ramin, Mathias Bressel, Sarah Everitt, et al.. (2021). Nodal metabolic tumour volume on baseline ¹⁸F‐FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative‐intent chemoradiotherapy/radiotherapy. Journal of Medical Imaging and Radiation Oncology. 65(6). 748–754. 2 indexed citations

11.

Wichmann, Christian, Peter Roselt, Stacey E. Rudd, et al.. (2021). AUTOMATED RADIOSYNTHESIS OF [(89)ZR]ZR-DFOSQ-DURVALUMAB ON THE IPHASE MULTISYN MODULE. Internal Medicine Journal. 51. 1206–1206. 3 indexed citations

12.

Seth, Ishith, et al.. (2021). ¹⁸ F‐FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta‐analysis. Pediatric Blood & Cancer. 69(3). e29415–e29415. 12 indexed citations

13.

Everitt, Sarah, Jeroen B. van de Kamer, Michael MacManus, et al.. (2020). Robust, independent and relevant prognostic 18F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?. PLoS ONE. 15(2). e0228793–e0228793. 19 indexed citations

14.

MacManus, Michael, Richard Fisher, Daniel Roos, et al.. (2018). Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. Journal of Clinical Oncology. 36(29). 2918–2925. 66 indexed citations

15.

Siva, Shankar, Pavel Lobachevsky, Michael MacManus, et al.. (2016). Radiotherapy for Non–Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues. Clinical Cancer Research. 22(19). 4817–4826. 57 indexed citations

16.

Hardcastle, Nicholas, Michael S. Hofman, Rodney J. Hicks, et al.. (2015). Accuracy and Utility of Deformable Image Registration in 68Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 93(1). 196–204. 22 indexed citations

17.

Siva, Shankar, Jason Callahan, Tomas Kron, et al.. (2014). A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. BMC Cancer. 14(1). 740–740. 31 indexed citations

18.

Everitt, Sarah, David Ball, Rodney J. Hicks, et al.. (2014). Differential ¹⁸F-FDG and ¹⁸F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non–Small Cell Lung Cancer. Journal of Nuclear Medicine. 55(7). 1069–1074. 57 indexed citations

19.

Campbell, Belinda A., Tsien Fua, Michael MacManus, et al.. (2012). Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leukemia & lymphoma. 54(3). 491–496. 31 indexed citations

20.

MacManus, Michael & John F. Seymour. (2001). Management of localized low‐grade follicular lymphomas. Australasian Radiology. 45(3). 326–334. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact